Qnexa phentermine/topiramate: Completed Phase III enrollment

Vivus completed enrollment of 2,500 overweight and obese adults with BMI between 27-45 and >=2 co-morbidities in the double-blind, U.S. Phase III CONQUER (OB-303) trial comparing 2 dosage strengths of...